Published in Cancer Res on April 01, 1975
Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol (2008) 1.91
alpha Fetoprotein producing early gastric cancer with liver metastasis: report of three cases. Gut (1991) 1.04
Early Detection of Cancer: Immunoassays for Plasma Tumor Markers. Expert Opin Med Diagn (2009) 1.04
Linkage of the evolutionarily-related serum albumin and alpha-fetoprotein genes within q11-22 of human chromosome 4. Am J Hum Genet (1983) 1.04
Alpha-fetoprotein concentrations measured by radioimmunoassay in diagnosing and excluding hepatocellular carcinoma. Br Med J (1978) 1.04
Clinicopathological characteristics of alpha-fetoprotein-producing gastric cancer. J Gastric Cancer (2011) 1.03
Elevated serum alpha-fetoprotein in a patient with undifferentiated carcinoma of the gall bladder. J Clin Pathol (1995) 1.01
Hepatoid adenocarcinoma of the stomach - a different histology for not so different gastric adenocarcinoma: a case report. Int Semin Surg Oncol (2009) 0.95
Alpha-fetoprotein-producing carcinoma of the colon: report of a case. Surg Today (1997) 0.94
Serum alpha1-foetoprotein levels in 153 male patients with germ cell tumours. Br J Cancer (1977) 0.94
Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans. Br J Cancer (1993) 0.90
Markers of bile duct tumors. World J Gastrointest Oncol (2011) 0.90
Liver metastasis is the only independent prognostic factor in AFP-producing gastric cancer. World J Gastroenterol (2013) 0.89
Differences between human and mouse alpha-fetoprotein expression during early development. J Anat (2001) 0.88
Antibody Arrays Identify Potential Diagnostic Markers of Hepatocellular Carcinoma. Biomark Insights (2008) 0.88
Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma. World J Gastroenterol (2005) 0.85
Clinicopathological characteristics and prognosis of alpha-fetoprotein positive gastric cancer in Chinese patients. Int J Clin Exp Pathol (2015) 0.82
Successful resection of metachronous liver metastasis from alpha-fetoprotein-producing gastric cancer: report of a case. Surg Today (1999) 0.82
Hepatoid adenocarcinoma of the lung: Presenting mediastinal metastasis without transfer to the liver. Oncol Lett (2014) 0.81
Pure alpha-fetoprotein-producing neuroendocrine carcinoma of the pancreas: a case report. BMC Gastroenterol (2015) 0.81
Low utility of plasma Nociceptin/orphanin FQ in the diagnosis of hepatocellular carcinoma. World J Gastroenterol (2006) 0.80
Alpha-fetoprotein-producing colon cancer with atypical bulky lymph node metastasis. World J Gastroenterol (2006) 0.79
Secretome survey of human plexiform neurofibroma derived Schwann Cells reveals a secreted form of the RARRES1 protein. Int J Mol Sci (2012) 0.79
The role of carbohydrate antigen 19-9 as a tumour marker of oesophageal cancer. Br J Cancer (1989) 0.78
Gastric composite tumor of alpha fetoprotein-producing carcinoma/hepatoid adenocarcinoma and endocrine carcinoma with reference to cellular phenotypes. Patholog Res Int (2012) 0.77
A unique case of an alpha-fetoprotein-producing lung cancer with testicular metastasis. Can Urol Assoc J (2012) 0.75
Successful multimodal therapy for an α-fetoprotein-producing gastric cancer patient with simultaneous liver metastases. Oncol Lett (2015) 0.75
Primary colon cancer with a high serum PIVKA-II level. Int J Surg Case Rep (2014) 0.75
Alpha-fetoprotein-producing early rectal carcinoma: a rare case report and review. World J Surg Oncol (2015) 0.75
Clinicopathological and prognostic characteristics in patients with AFP-secreting gastric carcinoma. Mol Clin Oncol (2017) 0.75
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol (1981) 10.92
A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature (1982) 9.42
Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia. Lancet (1974) 8.13
Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature (1984) 7.37
Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med (1991) 7.21
Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med (1985) 6.46
Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med (1980) 6.12
Metabolism of immunoglobulins. Prog Allergy (1969) 5.74
Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature (2011) 5.41
Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci U S A (1984) 4.90
Clustered arrangement of immunoglobulin lambda constant region genes in man. Nature (1981) 4.87
The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) (1985) 4.64
Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. Proc Natl Acad Sci U S A (1986) 4.61
The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. Proc Natl Acad Sci U S A (1989) 4.22
The physician's responsibility toward hopelessly ill patients. A second look. N Engl J Med (1989) 4.20
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol (1989) 4.03
Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA (1993) 3.91
Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. Proc Natl Acad Sci U S A (1985) 3.74
Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells. Proc Natl Acad Sci U S A (1981) 3.73
Human immunoglobulin kappa light-chain genes are deleted or rearranged in lambda-producing B cells. Nature (1981) 3.64
Immunoglobulin and other surface antigens of cells of the immune system. J Exp Med (1971) 3.50
Metabolic properties of IgG subclasses in man. J Clin Invest (1970) 3.48
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol (1989) 3.44
High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med (1985) 3.36
The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science (1986) 3.32
Expression of interleukin 2 receptors on activated human B cells. J Exp Med (1984) 3.27
Protein-losing enteropathy. Gastroenterology (1966) 3.21
Carcinoid tumors of the vermiform appendix. Cancer (1968) 3.07
The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med (1967) 3.06
Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med (1983) 2.96
Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med (1998) 2.95
Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet (1969) 2.94
Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins. J Clin Invest (1983) 2.91
Accelerated breakdown of immunoglobulin G (IgG) in myotonic dystrophy: a hereditary error of immunoglobulin catabolism. J Clin Invest (1966) 2.91
The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J Clin Invest (1972) 2.88
Relations between pancreatic enzyme ouputs and malabsorption in severe pancreatic insufficiency. N Engl J Med (1973) 2.81
IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A (2000) 2.80
The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A (1994) 2.79
Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr (1999) 2.79
Characterization of the human receptor for T-cell growth factor. Proc Natl Acad Sci U S A (1983) 2.76
Variable amplification of immunoglobulin lambda light-chain genes in human populations. Nature (1983) 2.75
Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sci U S A (1983) 2.73
Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med (1980) 2.72
Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med (1986) 2.70
Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. J Immunol (1983) 2.65
Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med (1979) 2.63
The Wiskott-Aldrich syndrome. A disorder with a possible defect in antigen processing or recognition. Lancet (1968) 2.61
Measurement of gastric functions during digestion of ordinary solid meals in man. Gastroenterology (1976) 2.56
A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A (1994) 2.51
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol (1998) 2.51
Ataxia-telangiectasia. Medicine (Baltimore) (1972) 2.50
The physician's responsibility toward hopelessly ill patients. N Engl J Med (1984) 2.46
The mechanism of appearance of immunoglobulin A in nasal secretions in man. J Clin Invest (1967) 2.45
Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol (1983) 2.41
The Sézary syndrome: a malignant proliferation of helper T cells. J Clin Invest (1976) 2.32
Surgical management of multiple polyposis. The problem of cancer in the retained bowel segment. Arch Surg (1970) 2.31
Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. J Clin Oncol (1985) 2.26
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med (1997) 2.25
Survival after postoperative combination treatment of rectal cancer. N Engl J Med (1986) 2.24
IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity (1996) 2.23
A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A (1989) 2.23
Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. Proc Natl Acad Sci U S A (1989) 2.23
The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. Proc Natl Acad Sci U S A (1987) 2.22
Separation of human blood monocytes and lymphocytes on a continuous Percoll gradient. J Immunol Methods (1980) 2.21
Regulation of interleukin 2 receptor expression: effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen. J Immunol (1984) 2.20
Dynamic, yet structured: The cell membrane three decades after the Singer-Nicolson model. Proc Natl Acad Sci U S A (2003) 2.20
Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature (1998) 2.17
Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet (1992) 2.15
Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A (1999) 2.14
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature (1989) 2.13
Only high-affinity receptors for interleukin 2 mediate internalization of ligand. Proc Natl Acad Sci U S A (1986) 2.12
Multiple primary malignant neoplasms: historical perspectives. Cancer (1977) 2.11
NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Ann Intern Med (1984) 2.10
A longitudinal survey of self-reported bowel habits in the United States. Dig Dis Sci (1989) 2.08
The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N Engl J Med (1977) 2.07
Systemic capillary leak syndrome and monoclonal IgG gammopathy; studies in a sixth patient and a review of the literature. Medicine (Baltimore) (1977) 2.07
T-lymphocyte interleukin 2-dependent tyrosine protein kinase signal transduction involves the activation of p56lck. Proc Natl Acad Sci U S A (1991) 2.03
Characterization of common variable immunodeficiency: identification of a subset of patients with distinctive immunophenotypic and clinical features. Blood (1990) 2.02
Novel T-lymphocyte population in combined immunodeficiency with features of graft-versus-host disease. N Engl J Med (1989) 1.99
Suppressor cells in the regulation of the immune response. Prog Clin Immunol (1977) 1.99
Augmented T cell growth factor receptor expression in HTLV-1-infected human leukemic T cells. J Immunol (1984) 1.99
Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. J Immunol (1987) 1.96
Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol (2000) 1.95
Control of gastric emptying by osmolality of duodenal contents in man. Gastroenterology (1975) 1.92
Controlled clinical studies of orally administered antiemetic drugs. Gastroenterology (1969) 1.92
Intestinal lymphangiectasia: a protein-losing enteropathy with hypogammaglobulinemia, lymphocytopenia and impaired homograft rejection. J Clin Invest (1967) 1.88
Simultaneous measurements of total pancreatic, biliary, and gastric outputs in man using a perfusion technique. Gastroenterology (1970) 1.86
Polyclonal B-cell activators in the study of the regulation of immunoglobulin synthesis in the human system. Adv Immunol (1982) 1.85
Defective lymphocyte transformation and delayed hypersensitivity in Wiskott-Aldrich syndrome. J Immunol (1970) 1.85
Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature (1985) 1.85
Comparative effects of antacids, cimetidine and enteric coating on the therapeutic response to oral enzymes in severe pancreatic insufficiency. N Engl J Med (1977) 1.85
Fate of orally ingested enzymes in pancreatic insufficiency. Comparison of two dosage schedules. N Engl J Med (1977) 1.84
The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer (1976) 1.81
Radioimmunoassay of conjugated cholyl bile acids in serum. Gastroenterology (1973) 1.81
The role of cell-surface receptors in the transport and catabolism of immunoglobulins. Ciba Found Symp (1972) 1.80